ATI RN
ATI Pharmacology Proctored Exam 2024
1. A client has a new prescription for Clonidine. What instruction should the nurse include during teaching?
- A. Take the medication with food.
- B. Expect to feel drowsy or lightheaded.
- C. Increase your fluid intake.
- D. Avoid foods high in fat.
Correct answer: B
Rationale: The correct instruction when teaching a client about Clonidine is to expect to feel drowsy or lightheaded. Clonidine can cause these side effects, especially when starting the medication. The nurse should advise the client to avoid activities that require alertness until they understand how the medication affects them. Choices A, C, and D are incorrect because taking Clonidine with food, increasing fluid intake, or avoiding foods high in fat are not specific instructions related to managing the side effects of Clonidine.
2. A healthcare provider is caring for a group of clients who are not protected against Varicella. The healthcare provider should prepare to administer the Varicella vaccine at this time to which of the following clients?
- A. 24-year-old woman in the third trimester of pregnancy
- B. 12-year-old child who has a severe allergy to neomycin
- C. 2-month-old infant who has no health problems
- D. 32-year-old man who has essential hypertension
Correct answer: D
Rationale: The correct answer is the 32-year-old man who has essential hypertension. Individuals who did not receive two doses of the varicella vaccine earlier in life should be immunized. Essential hypertension is not a contraindication for this vaccine, making it safe to administer to this client. Choice A is incorrect because administering the Varicella vaccine is contraindicated during pregnancy due to the risk of transmission to the fetus. Choice B is incorrect because a severe allergy to neomycin is a contraindication to the Varicella vaccine, which contains a trace amount of neomycin. Choice C is incorrect because the Varicella vaccine is not recommended for infants under 12 months of age.
3. A client is being discharged with a new prescription for Lisinopril. Which of the following instructions should be included by the healthcare provider?
- A. Avoid salt substitutes.
- B. Take this medication at bedtime.
- C. Increase your intake of potassium-rich foods.
- D. Take this medication with food.
Correct answer: A
Rationale: The correct answer is to instruct the client to avoid salt substitutes. Lisinopril, an ACE inhibitor, can lead to hyperkalemia, so it's essential to avoid salt substitutes that may contain potassium which can further elevate potassium levels. Choice B is incorrect because Lisinopril is typically taken once daily in the morning, not at bedtime. Choice C is incorrect as increasing potassium intake can exacerbate hyperkalemia when taking Lisinopril. Choice D is incorrect as Lisinopril is usually taken on an empty stomach, not with food.
4. A healthcare professional is reviewing the medical history of a client who has a new prescription for Metformin to treat type 2 diabetes. Which of the following findings should the healthcare professional report to the provider?
- A. Hemoglobin A1C of 7.5%
- B. Creatinine level of 1.2 mg/dL
- C. BUN level of 18 mg/dL
- D. Liver function tests showing AST of 50 units/L
Correct answer: D
Rationale: The correct answer is D. Elevated AST levels in liver function tests should be reported to the provider when a client is prescribed Metformin due to the potential risk of hepatotoxicity associated with the medication. Elevated Hemoglobin A1C (choice A), Creatinine level within normal range (choice B), and BUN level within normal range (choice C) are not directly concerning when initiating Metformin therapy.
5. A client is receiving daily doses of Oprelvekin. Which of the following laboratory values should be monitored to determine the effectiveness of this medication?
- A. Hemoglobin
- B. Absolute neutrophil count
- C. Platelet count
- D. Total white blood cell count
Correct answer: C
Rationale: Oprelvekin is a medication that stimulates platelet production. Therefore, monitoring the platelet count is essential to assess the effectiveness of this drug. The expected outcome for oprelvekin therapy is a platelet count greater than 50,000/mm^3. Changes in platelet count can indicate the response to the medication and help in adjusting the treatment plan accordingly. Monitoring hemoglobin, absolute neutrophil count, or total white blood cell count is not directly related to the mechanism of action of Oprelvekin and therefore would not provide accurate information on the drug's effectiveness.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access